According to the Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation there is insufficient data to evaluate the efficacy of switching to mTOR inhibitors for treating BKPyV-DNAemia or biopsy-proven BKPyV-nephropathy [23]. The gene discussed is MTOR; the disease is Nephropathy.